Submit justification: CDSCO panel tells Hetero for FDC Lacosamide, Brivaracetam - Video
|
Overview
In line with the drug maker Hetero Pharma's proposal for the fixed-dose combination Lacosamide plus Brivaracetam, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit the justification in respect to the combination drug to the CDSCO for further review by the committee.
This came after the drug maker Hetero Pharma presented its proposal along with bioequivalence (BE) and Phase III clinical trial protocol before the committee.
For more details, check out the full story on the link below:
Submit Justification: CDSCO Panel Tells Hetero For FDC Lacosamide, Brivaracetam
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
